AbbVie

AbbVie NYSE: ABBV shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. The fear of rapidly declining Humira sales was not offset by hope driven by new products such as Skyrizi and Rinvoq. The takeaway for today is that Humira sales may already be…

Samsung Electronics reported an 86% decrease in net income in the quarter ending in June, but confidently pledged to continue cutting memory chip production while forecasting a sales rebound in the second half of the year. The company believes that artificial intelligence (AI) demand will contribute to increased memory demand by the end of the…

After U.S. markets closed on Wednesday, Mattel reported higher-than-expected earnings per share (EPS), posting a profit of $0.10 compared to an expected loss of $0.03. Additionally, the company’s revenue came in 8.7% above consensus forecasts. Mattel also reaffirmed its guidance. As a result, the stock saw a 3% increase shortly after Thursday’s opening bell. Meta…

July 12, 2023 2 min watch …

Using an AI + Human in the Loop (HITL) approach can be utilized for Study Data Tabulation Model (SDTM) transformation, potentially alleviating current challenges The Study Data Tabulation Model (SDTM) is a set of standards developed by the Clinical Data Interchange Standards Consortium (CDISC) to exchange clinical data. SDTM is an essential standard for organizing…

Regenerative and aesthetic medicine company CollPlant Biotechnologies ((NASDAQ: CLGN) has reached a significant milestone in its collaboration with pharma giant AbbVie for the development of a regenerative dermal and soft tissue filler product. Reaching the milestone triggers a $10 million payment to CollPlant. The collaboration between CollPlant and AbbVie began in 2021 when the entered…

@Nathan Aisenstadt This didn't cause you by surprise, did it? If you haven't considered the impact of Hadlima on Humira sales, you might also want to consider Boehringer's Cyltezo (also available since July 01 in the U.S.): www.boehringer-ingelheim.com/...As an aside, Humira LOE'ed in the E.U. back in 2018, since then severeal biosimilars got approved, so…

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said AbbVie Inc. ABBV has a 4.5% yield and high free cash flow yield. AbbVie reported reimbursement for VRAYLAR for the treatment of schizophrenia under Non-Insured Health Benefits (NIHB) Program. Stephen Weiss of Short Hills Capital…

MILAN, Italy — Two independent efforts to use artificial intelligence (AI) to predict the development of early rheumatoid arthritis (RA) from patients with signs and symptoms not meeting full disease criteria showed good, near expert-level accuracy, according to findings from two studies presented at the European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Meeting.…

Health Canada approved AbbVie's (ABBV) Rinvoq to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Read more here

Artificial intelligence (AI) permeated industries for years, but the release of ChatGPT thrust it into the limelight. It's the talk of the investment community and around the water coolers across the country. But what exactly is it? AI extends far beyond "intelligent" (and sometimes sinister) robots in the movies or Chatbots like ChatGPT. At its…

Text size …